Ocugen (OCGN) H.C. Wainwright – Biotech "On Tap" 2025 summary

Strategic focus and pipeline overview

• Targeting gene therapies for major blindness diseases: retinitis pigmentosa, Stargardt disease, and geographic atrophy, with three BLA submissions planned between 2026 and 2028.

• Lead candidate OCU400 is in Phase 3 for retinitis pigmentosa, aiming for broad coverage of mutations and a BLA submission in 2026.

• OCU410ST for Stargardt disease and OCU410 for geographic atrophy are also advancing, with OCU410 targeted for BLA in 2028.

• Mission includes global market access and addressing significant unmet needs in vision loss.

Technology and clinical approach

• Modifier gene therapy platform enables treatment across multiple mutations and disease forms, resetting cellular homeostasis.

• OCU400 covers 98-99% of RP mutations, unlike existing therapies limited to specific mutations.

• OCU410 targets four disease mechanisms: complement system, oxidative stress, lipid metabolism, and inflammation.

• Clinical trials show promising safety, durability, and efficacy, with no serious adverse events reported.

Clinical trial design and progress

• OCU400 Phase 3 (liMeliGhT) enrolls 150 subjects, split between rhodopsin and gene-agnostic arms, with primary endpoint based on luminance-dependent navigation assessment.

• Phase 1/2 data for OCU400 demonstrated 24-month durability and statistically significant improvements in visual acuity.

• EMA has agreed to accept U.S. trial data for European submission, with centralized procedure preparation underway.

• OCU410ST for Stargardt disease uses an adaptive Phase 2/3 design, showing a 48% lesion size reduction at 12 months.